Kashfi Simon, Marneni Naimisha, Sharma Shorabh, Vigoda Ivette
Internal Medicine, City University of New York (CUNY) School of Medicine, New York, USA.
Internal Medicine, St. Barnabas Hospital Health System, Bronx, USA.
Cureus. 2022 Mar 17;14(3):e23250. doi: 10.7759/cureus.23250. eCollection 2022 Mar.
Mucosal melanomas represent about 1% of all melanoma cases. Primary malignant melanoma of the esophagus (PMME) is a rare and deadly condition, with only about 339 cases reported in the literature. Esophageal melanoma usually presents with progressively worsening dysphagia, and patients often present late in the disease course. Esophageal melanoma can be treated with surgical resection, chemotherapy, targeted therapy, or immunotherapy depending on the stage and tumor mutations. However, due to the rarity of the disease, no trials have been performed to deliver a gold standard of treatment. We present the case of a 76-year-old female who was diagnosed with metastatic primary malignant melanoma of the esophagus and underwent treatment with nivolumab, a PD-1 receptor antagonist.
黏膜黑色素瘤约占所有黑色素瘤病例的1%。食管原发性恶性黑色素瘤（PMME）是一种罕见且致命的疾病，文献中仅报道了约339例。食管黑色素瘤通常表现为进行性加重的吞咽困难，患者往往在疾病病程晚期才出现症状。根据分期和肿瘤突变情况，食管黑色素瘤可通过手术切除、化疗、靶向治疗或免疫治疗。然而，由于该疾病罕见，尚未进行试验以提供治疗的金标准。我们报告一例76岁女性患者，她被诊断为食管转移性原发性恶性黑色素瘤，并接受了PD -1受体拮抗剂纳武单抗治疗。
